UK-based gene and cell therapy group Oxford Biomedica has sold its Windrush Court facility in Oxford to Kadans Science Partner for £60 mln (€68 mln).
UK-based gene and cell therapy group Oxford Biomedica has sold its Windrush Court facility in Oxford to Kadans Science Partner for £60 mln (€68 mln).
A 4-acre, freehold site at Kings Cross in the capital’s Knowledge Quarter is expected to attract international interest.